Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 16/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12183367 | 0.87 | PDE10A (0.50) | PDE10AKDM4EHTR2B | |
| SCHEMBL2593448 | 0.85 | PDE10A (0.46) | PDE10AALDH1A1LMNA | |
| SCHEMBL2593454 | 0.85 | PDE10A (0.47) | PDE10AALDH1A1 | |
| SCHEMBL2595631 | 0.84 | PDE10A (0.47) | PDE10A | |
| SCHEMBL9994552 | 0.84 | PDE10A (0.46) | PDE10AKDM4EALDH1A1LMNA | |
| SCHEMBL9994825 | 0.81 | TRPV1 (0.50) | PDE10ALMNA | |
| SCHEMBL2589976 | 0.81 | PDE10A (0.46) | PDE10AALDH1A1 | |
| SCHEMBL9994963 | 0.80 | ALDH1A1 (0.45) | PDE10AKDM4EALDH1A1L3MBTL1LMNA | |
| SCHEMBL2596257 | 0.80 | PDE10A (0.49) | PDE10A | |
| SCHEMBL2593440 | 0.80 | PDE10A (0.49) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946230-B2 | Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-03 | — | — | US | claimed |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | claimed |
| US-8946230-B2 | Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946230-B2 | Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946230-B2 | Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| WO-2011143129-A1 | NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | HDAC10, PDE10A, PDE9A | PDE10A 2/4885BCHE 761/4885KDM4E 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.